Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Effect of MSCs on vascular endothelial growth factor (VEGF), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), triglyceride, pancreatic beta cells and insulin resistance in Oobese Type 2 diabetic rat m

Mahendra Eka Saputra V., Putra A., Sumarawati T., Ibrahim S., Mila MN., Antari AD.

Animal Study on Type 2 Diabetes, published in Med Glas (Zenica) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Med Glas (Zenica) (2025)
Country
Bosnia and Herzegovina
Reported sample size
—
Source database
PubMed
PMID
41082746
DOI
10.17392/1979-22-02

Abstract (original English)

Aim to investigate the potential of SG followed by injection of MSCs in type 2 diabetic rats with obesity in improving IR. Methods This study used a pre and post-control group design with 24 rats divided into three groups: Control (C), SG, and SG + MSCs (SG+M). On day 10, the level of vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), triglyceride (TG), pancreatic beta cells, and homeostasis model assessment of IR (HOMA-IR) was evaluated using qRT-PCR, ELISA, and immunohistochemistry. Results A significant decrease of TNF-α (1.179 pg/mL), CRP(209 pg/mL), and TG levels (82,83  15,02pg/mL) in all treatment groups on day 10, in which SG + M group showed optimum inhibition was found (p < 0.05). This result was in line with the optimum increase of VEGF (8,1500 ± 2,47397) and pancreatic beta cell(10,1783±0,47) in SG + M group (p < 0.05). Moreover, our study also revealed the optimum decrease of HOMA-IR in SG+M group on day 10 (49,8233 ± 1,07303). Conclusion A combination of SG and MSCs can optimally improve insulin resistance by inhibiting TNF-α, CRP, and TG level and upregulating VEGF and pancreatic beta cell in an obese T2DM rat model.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsInsulin ResistanceTumor Necrosis Factor-alphaVascular Endothelial Growth Factor ARatsTriglyceridesInsulin-Secreting CellsC-Reactive ProteinDiabetes Mellitus, Type 2Male

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research